Clinical efficacy of cefpodoxime in respiratory tract infection

Size: px
Start display at page:

Download "Clinical efficacy of cefpodoxime in respiratory tract infection"

Transcription

1 Journal of Antimicrobial Chemotherapy (2002) 50, Topic T1, DOI: /jac/dkf805 Clinical efficacy of cefpodoxime in respiratory tract infection Robert Cohen* Department of Microbiology, Intercommunal Hospital of Créteil, Créteil, France Acute otitis media (AOM), sinusitis and tonsillopharyngitis are respiratory tract infections frequently encountered by primary-care physicians. Increasing bacterial resistance, particularly in Streptococcus pneumoniae, which is one of the most important respiratory tract bacteria implicated in community-acquired respiratory tract infections, has led to concern about the current options for empirical antibiotic treatment and has prompted a search for effective alternative treatments. Data from in vitro studies show that cefpodoxime has good activity against the main respiratory tract pathogens, S. pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pyogenes. Clinical studies confirm the efficacy of cefpodoxime in AOM, sinusitis and tonsillopharyngitis. As with all broad-spectrum antibiotics, there is the risk of promotion of bacterial resistance associated with overuse. However, if used with care, cefpodoxime can be considered as an alternative for empirical treatment of bacterial respiratory tract infections encountered in general practice, particularly where penicillins and macrolides have reduced efficacy against the main bacterial pathogens. Introduction Community-acquired respiratory tract infections, in particular acute otitis media (AOM), sinusitis and tonsillopharyngitis, are among the most common reasons for general practice consultation, accounting for more than 50% of paediatric consultations and more than 75% of antibiotic prescriptions for out-patients. 1 The most important bacterial pathogens in AOM and sinusitis are Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis, and in tonsillopharyngitis, Streptococcus pyogenes. As the bacterial aetiology of infection is usually not confirmed prior to initiation of treatment, empirical antibiotic therapy needs to take account of the major causative bacteria. However, increasing bacterial resistance, particularly penicillin and macrolide resistance among S. pneumoniae isolates, 2 has led to growing concern about current options for empirical therapy and has prompted a search for other effective treatments. This article examines the clinical and bacteriological efficacy of the oral cephalosporin, cefpodoxime, for treatment of bacterial AOM, sinusitis and tonsillopharyngitis. Acute otitis media Acute otitis media is particularly distressing for children, and prompt effective treatment is required for symptom relief, as well as for prevention, as far as possible, of long-term sequelae, such as hearing loss and permanent middle-ear damage. Currently, S. pneumoniae is regarded as the principal clinically important bacterial cause of AOM, with amoxicillin indicated for first-line therapy. 3 The importance of H. influenzae as a cause of non-responsive AOM should also be borne in mind. 4 It is possible that preventative measures such as the implementation of vaccination programmes for pneumococcal infection may diminish the importance of S. pneumoniae, resulting in H. influenzae becoming the main pathogen in AOM. 5 An antibiotic with a spectrum of antibacterial activity covering both S. pneumoniae and H. influenzae and effective against penicillin-susceptible and penicillin-intermediate strains of S. pneumoniae is necessary to achieve good bacteriological and clinical efficacy and to help prevent the development of resistance. Data from in vitro studies indicate that cefpodoxime, an oral cephalosporin with a broad spectrum of antibacterial activity, may be an appropriate treatment choice in bacterial AOM, as well as in sinusitis, which shares a similar aetiology. Cefpodoxime is active against penicillin-susceptible S. pneumoniae, with MIC 90 values ranging from <0.06 mg/l to <0.25 mg/l, as well as against penicillin-intermediate strains of S. pneumoniae (MIC mg/l). 6 It also shows good activity against H. influenzae (including β-lactamaseproducing strains), with MIC 90 values ranging from <0.03 mg/l to 0.13 mg/l. 6 In a study conducted in the USA, cefpodoxime... *Correspondence address. Centre Hospitalier de Créteil, Créteil Cedex, France. Tel: ; Fax: ; robert.cohen@wanadoo.fr The British Society for Antimicrobial Chemotherapy

2 R. Cohen Table 1. Summary of comparative clinical studies in paediatric patients with acute otitis media using cefpodoxime Study (no. of patients) Treatment regimen Mean age (years) Clinical endpoint Clinical efficacy at end of treatment [n/total cases (%)] Mendelman et al. (1992) 7 cefpodoxime 10 mg/kg/day, 10 days 3.4 cure + improvement 90/98 (92) (n = 229) co-amoxiclav 40/10 mg/kg/day, 10 days /48 (88) Cohen et al. (1994) 8 cefpodoxime 8 mg/kg/day, 8 days 1.9 cure + improvement 61/69 (88) a (n = 146) cefixime 8 mg/kg/day, 8 days /71 (73) Gehanno et al. (1994) 9 cefpodoxime 8 mg/kg/day, 8 days 2.8 cure + improvement 112/118 (95) (n = 262) cure 71/118 (60) b co-amoxiclav 40/10 mg/kg/day, 8 days 3.1 cure + improvement 100/105 (95) cure 42/105 (40) Fernández MacLoughlin et al. cefpodoxime 10 mg/kg/day, 5 days 3.5 cure + improvement 73/78 (94) (1996) 10 (n = 167) cefaclor 40 mg/kg/day, 5 days /83 (92) Cohen et al. (1997) 11 cefpodoxime 8 mg/kg/day, 5 days 1.6 cure + improvement 160/186 (86) (n = 398) co-amoxiclav 80/10 mg/kg/day, 8 days /184 (83) a Cefpodoxime versus cefixime, P <0.05 ; b cefpodoxime versus AMC, P <0.005 (χ 2 or Fisher s exact tests; 95% confidence intervals). exhibited greater in vitro activity against S. pneumoniae than did cefaclor, cefuroxime, cefprozil, cefixime or loracarbef. 6 Moreover, pharmacodynamic and pharmacokinetic properties of cefpodoxime are favourable, because effective concentrations of cefpodoxime in the middle-ear fluid of paediatric patients are achieved with recommended dosing schedules. 6 Clinical data show that cefpodoxime is an effective treatment for bacterial AOM in children. Table 1 shows the results of five multicentre, randomized trials comparing the clinical efficacy of cefpodoxime with co-amoxiclav, cefixime or cefaclor in a total of 1202 paediatric patients The duration of treatment with cefpodoxime ranged from 5 to 10 days. In three of these trials, cefpodoxime was clinically at least as effective as the treatment used for comparison. In the other two trials, treatment with cefpodoxime demonstrated significantly greater clinical efficacy and cure rates than either cefixime or co-amoxiclav, respectively. 8,9 Clinical trials often fail to show a difference in clinical efficacy between antibiotic treatments, and there are currently no definitive trials of bacteriological efficacy in childhood AOM. Alternative methods of assessing antibiotics, such as the in vivo sensitivity test to assess bacteriological efficacy by examining fluid acquired by a tympanocentesis before and a few days after the start of treatment, and retrospective analyses of treatment failures, have therefore been investigated. Such analyses show good bacteriological efficacy for cefpodoxime against H. influenzae and penicillin-susceptible S. pneumoniae (Figure 1) Moreover, the less frequent dosing schedule of cefpodoxime (bd) compared with either co-amoxiclav or cefaclor (tds), would be an added advantage for treatment with cefpodoxime. Figure 1. Comparison of eradication rates for (a) H. influenzae and (b) penicillin-susceptible S. pneumoniae in acute otitis media using data from the in vivo sensitivity test to assess bacteriological efficacy and retrospective analyses of treatment failures. Filled bars, bacteriological failure; open bars, eradication. Data from Klein 17 except for: *Klein 17 and Dagan et al. 18 ; Dagan et al. 19,20. 24

3 Cefpodoxime in respiratory tract infection Acute sinusitis The treatment of acute sinusitis is complicated by a difficulty in establishing the causative bacteria. In AOM, sampling of ear fluid using tympanocentesis is a routine procedure in some countries, whereas in sinusitis, sampling of infected fluid using sinus puncture is a painful and rare procedure. Consequently, empirical treatment of acute sinusitis of suspected bacteriological aetiology is the approach usually adopted. Selection of appropriate antibiotic therapy should take account of the most likely causative bacteria, local patterns of bacterial resistance and the pharmacokinetic profile of the antibiotic. Co-amoxiclav is currently regarded as first-line therapy for acute bacterial sinusitis. 21 However, the increasing prevalence of resistant strains among the main pathogens of acute sinusitis does suggest the need for effective treatment alternatives. As the bacterial aetiology of acute sinusitis is similar to that observed with AOM, cefpodoxime, which shows good in vitro activity against both S. pneumoniae and H. influenzae, 6 may be an appropriate alternative. Data from clinical trials show that treatment with cefpodoxime is clinically at least as effective as amoxicillin or co-amoxiclav in both adults and children Moreover, clinical cure rates in adults with acute sinusitis are significantly better after a 10 day treatment course with cefpodoxime than with cefaclor (Table 2). 25 Tonsillopharyngitis Acute tonsillopharyngitis is one of the most common reasons for consultation in general practice. 26 In most countries, antibiotic treatment is definitely indicated for treatment of group A β-haemolytic streptococci (GABHS), the most common bacterial cause of acute tonsillopharyngitis, to prevent suppurative complications and serious sequelae such as acute rheumatic fever or glomerulonephritis. Clinical diagnosis of GABHS infection is, however, difficult, because many of the signs and symptoms of GABHS tonsillopharyngitis are nonspecific and are indistinguishable from viral infections, even for experienced clinicians. Diagnosis of GABHS requires confirmation by either rapid antigen test or culture prior to initiation of antibiotic therapy. 26 Traditionally, oral penicillin therapy for 10 days has been regarded as the treatment of choice for GABHS tonsillopharyngitis because of its proven efficacy, narrow spectrum of antibacterial activity and tolerability. 27 Although effective in most patients, the treatment failure rates with penicillin are typically in the region of 10 30%, 28 while the causative pathogen remains susceptible to β-lactam therapy. Possible reasons for this observed failure rate include poor compliance and co-pathogen colonization with, for example, Staphylococcus aureus, H. influenzae or M. catarrhalis, which produce β-lactamase, thereby inactivating penicillin before it can exert any effect. Therefore, antibiotics that have high potency against GABHS are β-lactamase stable, and are effective in a shorter regimen, are preferred. Macrolide therapy is a possible alternative treatment. The increased prevalence of macrolide resistance, particularly in Italy and Spain, should, however, be considered. 2 Cefpodoxime has good in vitro activity against S. pyogenes, with an MIC 90 of <0.06 mg/l. 6 Clinical studies show that treatment with cefpodoxime 200 mg daily for 5 10 days is at least as effective in eradicating GABHS as a standard 10-day treatment course of penicillin in both adult and paediatric patients In studies in paediatric patients (Table 3), the rate of bacterial eradication following a 5 day or 10 day course of cefpodoxime was significantly higher than that observed following treatment with penicillin V for 10 days. 30,32 Table 2. Summary of comparative clinical trials in adult and paediatric patients with acute sinusitis Study (no. of patients) Treatment regimen Mean age (years) Clinical endpoint Clinical efficacy at end of treatment [n/total cases (%)] Gehanno et al. (1990) 25 cefpodoxime 400 mg/day, 10 days 41.3 cure + improvement 116/122 (95) (n = 267) cure 102/122 (84) a cefaclor 1500 mg/day, 10 days 42.1 cure + improvement 106/114 (93) cure 77/114 (68) Von Sydow et al. (1995) 22 cefpodoxime 400 mg/day, 10 days 33.0 cure + improvement 112/117 (96) (n = 286) amoxicillin 1500 mg, 10 days /113 (91) Autret et al. (1994) 23 cefpodoxime 8 mg/kg/day, 10 days 6.9 cure + improvement 42/44 (95) (n = 116) co-amoxiclav 40/10 mg/kg/day, 10 days /28 (82) Sabater et al. (1995) 24 cefpodoxime 400 mg/day, 5 days 35.5 cure + improvement 32/32 (100) (n = 66) co-amoxiclav 1500/375 mg/day, 8 days /33 (97) a Cefpodoxime versus cefaclor, P <

4 R. Cohen Table 3. Summary of comparative clinical trials in adult and paediatric patients with group A β-haemolytic streptococcal tonsillopharyngitis Study (no. of patients) Treatment regimen Mean age (years) Bacteriological efficacy [eradication/total cases (% eradication)] Brown et al. (1991) 29 cefpodoxime 200 mg/day, 10 days /30 (97) (n = 93) penicillin V 1 g/day, 10 days /33 (91) Dajani et al. (1993) 30 cefpodoxime 10 mg/kg/day, 10 days /275 (93) c (n = 578) penicillin V 40 mg/kg/day, 10 days /138 (81) Portier et al. (1994) 31 cefpodoxime 200 mg/day, 5 days /82 (96) (n = 220) penicillin V 1800 mg/day, 10 days /68 (94) Pichichero et al. (1994) 32 cefpodoxime 10 mg/kg/day, 5 days /125 (90) a (n = 484) cefpodoxime 10 mg/kg/day, 10 days /118 (95) b penicillin V 40 mg/kg/day, 10 days /129 (78) χ 2 Or Fisher s exact test: a Cefpodoxime 5 days versus penicillin V, P <0.05; b cefpodoxime 10 days versus penicillin V, P <0.005; c cefpodoxime versus penicillin V, P <0.01. Given the fact that poor compliance is an important contributing factor to bacteriological treatment failure in GABHS tonsillopharyngitis, cefpodoxime, given over a 5 10 day period, may be a suitable treatment option. Discussion Cefpodoxime has good in vitro activity against the bacterial pathogens that are responsible for common respiratory tract infections such as AOM, acute sinusitis and tonsillopharyngitis. Clinical studies show that cefpodoxime is at least as effective as standard first-line antibiotic therapy for each of these indications. As with all broad-spectrum antibiotics, there is the risk of increased resistance if they are overused or used inappropriately. 33 However, if used with care, cefpodoxime can be considered as an appropriate choice for the empirical treatment of community-acquired respiratory tract infection caused by bacteria, particularly where there is emerging resistance to traditional antimicrobial chemotherapy. References 1. Shappert, S. M. (1992). Office visits for otitis media: United States, In Vital and Health Statistics of the Centers for Disease Control/National Center for Health Statistics No. 214, pp US Department of Health and Human Services, Hyattsville, MD. 2. Felmingham, D. & Gruneberg, R. N. (2000). The Alexander Project : latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 45, Olson, L. C. & Jackson, M. A. (1999). Only the pneumococcus. Pediatric Infectious Disease Journal 18, Musher, D. & Dagan, R. (2000). Is the pneumococcus the one and only in acute otitis media? Pediatric Infectious Disease Journal 19, Eskola, J., Kilpi, T., Palmu, A., Jokinen, J., Haapakoski, J., Herva, E. et al. (2001). Efficacy of a pneumococcal conjugate vaccine against acute otitis media. New England Journal of Medicine 344, Fulton, B. & Perry, C. M. (2001). Cefpodoxime proxetil. A review of its use in the management of bacterial infections in paediatric patients. Paediatric Drugs 3, Mendelman, P. M., Del Beccaro, M. A., McLinn, S. E. & Todd, W. M. (1992). Cefpodoxime proxetil compared with amoxicillinclavulanate for the treatment of otitis media. Journal of Pediatrics 121, Cohen, R., de La Rocque, F., Boucherat, M., Grandsenne, Ph., Corrard, F., Bouhanna, Ch. A. et al. (1994). Cefpodoxime proxetil vs cefixime for painful febrile acute otitis media in children. Médecine et Maladies Infectieuses 24, Gehanno, P., Barry, B., Bobin, S. & Safran, C. (1994). Twice daily cefpodoxime proxetil compared with thrice daily amoxicillin/ clavulanic acid for treatment of acute otitis media in children. Scandinavian Journal of Infectious Diseases 26, Fernández MacLoughlin, G. J., F, Barreto, D. G., de la Torre, C., Pinetta, E. A., del Castillo, F. & Palma, L. (1996). Cefpodoxime proxetil suspension compared with cefaclor suspension for treatment of acute otitis media in paediatric patients. Journal of Antimicrobial Chemotherapy 37,

5 Cefpodoxime in respiratory tract infection 11. Cohen, R., de La Rocque, F., Boucherat, M., Lévy, C., Langue, J. & Bourrillon, A. (1997). Randomized trial comparing 5-day cefpodoxime proxetil and 8-day amoxicillin-clavulanate treatment of acute otitis media in children. Médecine et Maladies Infectieuses 27, Howie, V. M. & Ploussard, J. H. ( 1969). The in vivo sensitivity test bacteriology of middle ear exudate, during antimicrobial therapy in otitis media. Pediatrics 44, Howie, V. M., Dillard, R. & Lawrence, B. (1985). In vivo sensitivity test in otitis media: efficacy of antibiotics. Pediatrics 75, Howie, V. M. & Owen, M. J. (1987). Bacteriologic and clinical efficacy of cefixime compared with amoxicillin in acute otitis media. Pediatric Infectious Disease Journal 6, Howie, V. M. (1993). Otitis media. Pediatrics Review 14, Howie, V. M. (1992). Eradication of bacterial pathogens from middle ear infections. Clinical Infectious Diseases 14, Suppl. 2, Klein, J. (1993). Microbiologic efficacy of antibacterial drugs for acute otitis media. Pediatric Infectious Disease Journal 12, Dagan, R., Abramson, O., Leibovitz, E., Lang, R., Goshen, S., Greenberg, D. et al. (1996). Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin. Pediatric Infectious Disease Journal 15, Dagan, R., Leibovitz, E., Fliss, D. M., Leiberman, A., Jacobs, M. R., Craig, W. et al. (2000). Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrobial Agents and Chemotherapy 44, Dagan, R., Johnson, C., McLinn, S., Abughali, N., Feris, J., Leibovitz, E. et al. (2000). Bacteriologic and clinical efficacy of amoxicillin/clavulanate versus azithromycin in acute otitis media. Pediatric Infectious Disease Journal 19, Low, D. E., Desrosiers, M., McSherry, J., Garber, G., Williams, J. W., Jr, Remy, H. et al. (1997). A practical guide for the diagnosis and treatment of acute sinusitis. Canadian Medical Association Journal 156, Suppl. 6, S1 S Von Sydow, C., Savolainen, S. & Soderqvist, A. ( 1995). Treatment of acute maxillary sinusitis comparing cefpodoxime proxetil with amoxicillin. Scandinavian Journal of Infectious Diseases 27, Autret, E., Boulesteix, J., Smit, C. J., Marticou, L. & Safran, C. (1994). Comparative safety and efficacy of cefpodoxime proxetil and amoxicillin/clavulanic acid in the treatment of acute maxillary sinusitis in children. In Recent Advances in Chemotherapy: Proceedings of the 18th International Congress of Chemotherapy, Stockholm, Sweden, June 27 July Abstract 852. American Society for Microbiology, Washington, DC. 24. Sabater, F., Larrosa, F., Guiroa, M., Ciges, M., Figuerola, A. & Fernandez, F. (1995). Cefpodoxime proxetil (5 days) vs amoxicillin/ clavulanic acid (8 days) in the treatment of acute maxillo-ethmoidal sinusitis in adult outpatients. Canadian Journal of Infectious Diseases 6, Suppl. C, Abstract Gehanno, P., Depondt, J., Barry, B., Simonet, M. & Dewever, H. (1990). Comparison of cefpodoxime proxetil with cefaclor in the treatment of sinusitis. Journal of Antimicrobial Chemotherapy 26, Suppl. E, Bisno, A. L., Gerber, M. A., Gwaltney, J. M., Jr, Kaplan, E. L. & Schwartz, R. H. (1997). Diagnosis and management of group A streptococcal pharyngitis: a practice guideline. Clinical Infectious Diseases 25, Bisno, A. L. (2001). Acute pharyngitis. New England Journal of Medicine 344, Pichichero, M. E. (1995). Shortened regimens for pharyngitis/ tonsillitis. Hospital Practice 31, Brown, R. J., Batts, D. H., Hughes, G. S. & Greenwald, C. A. (1991). Comparison of oral cefpodoxime proxetil and penicillin V potassium in the treatment of group A streptococcal pharyngitis/ tonsillitis. The Cefpodoxime Pharyngitis Study Group. Clinical Therapeutics 13, Dajani, A. S., Kessler, S. L., Mendelson, R., Uden, D. L. & Todd, W. M. (1993). Cefpodoxime proxetil vs. penicillin V in pediatric streptococcal pharyngitis/tonsillitis. Pediatric Infectious Disease Journal 12, Portier, H., Chavanet, P., Waldner-Combernoux, A., Kisterman, J. P., Grey, P. C., Ichou, F. et al. (1994). Five versus ten days treatment of streptococcal pharyngotonsillitis: a randomized controlled trial comparing cefpodoxime proxetil and phenoxymethyl penicillin. Scandinavian Journal of Infectious Diseases 26, Pichichero, M. E., Gooch, W. M., Rodriguez, W., Blumer, J. L., Aronoff, S. C., Jacobs, R. F. et al. (1994). Effective short-course treatment of acute group A beta-hemolytic streptococcal tonsillopharyngitis. Ten days of penicillin V vs 5 days or 10 days of cefpodoxime therapy in children. Archives of Pediatric and Adolescent Medicine 148, Carrie, A. G. & Zhanel, G. G. (1999). Antibacterial use in community practice: assessing quantity, indications and appropriateness, and relationship to the development of antibacterial resistance. Drugs 57,

6

Srirupa Das, Associate Director, Medical Affairs, Tushar Fegade, Manager, Clinical Research Abbott Healthcare Private Limited, Mumbai.

Srirupa Das, Associate Director, Medical Affairs, Tushar Fegade, Manager, Clinical Research Abbott Healthcare Private Limited, Mumbai. Indian Medical Gazette JUNE 2015 225 Comparative A Randomized, Open Label, Prospective, Comparative Evaluating the Efficacy and Safety of Fixed Dose Combination of Cefpodoxime 200 Mg + Clavulanic Acid

More information

11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1

11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1 Disclosures Selecting Antimicrobials for Common Infections in Children FMR-Contemporary Pediatrics 11/2016 Sean McTigue, MD Assistant Professor of Pediatrics, Pediatric Infectious Diseases Medical Director

More information

Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children

Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children Prescribing Antimicrobials for Common Illnesses When treating common illnesses such as ear infections and strep throat,

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Gerber JS, Prasad PA, Fiks AG, et al. Effect of an outpatient antimicrobial stewardship intervention on broad-spectrum antibiotic prescribing by primary care pediatricians:

More information

Keywords: amoxicillin/clavulanate, respiratory tract infection, antimicrobial resistance, pharmacokinetics/pharmacodynamics, appropriate prescribing

Keywords: amoxicillin/clavulanate, respiratory tract infection, antimicrobial resistance, pharmacokinetics/pharmacodynamics, appropriate prescribing Journal of Antimicrobial Chemotherapy (2004) 53, Suppl. S1, i3 i20 DOI: 10.1093/jac/dkh050 Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review

More information

The Turkish Journal of Pediatrics 2008; 50:

The Turkish Journal of Pediatrics 2008; 50: The Turkish Journal of Pediatrics 2008; 50: 120-125 Original Comparison of the effect of benzathine penicillin G, clarithromycin, cefprozil and amoxicillin/clavulanate on the bacteriological response and

More information

Rational use of antibiotic in upper respiratory tract infection (URI) and community acquired pneumonia รศ.จามร ธ รตก ลพ ศาล 23 พฤษภาคม 2550

Rational use of antibiotic in upper respiratory tract infection (URI) and community acquired pneumonia รศ.จามร ธ รตก ลพ ศาล 23 พฤษภาคม 2550 Rational use of antibiotic in upper respiratory tract infection (URI) and community acquired pneumonia รศ.จามร ธ รตก ลพ ศาล 23 พฤษภาคม 2550 Sinusitis Upper respiratory tract infections (URI) Common cold

More information

Antibiotics & treatment of Acute Bcterial Sinusitis. Walid Reda Product Manager. Do your antimicrobial options meet your needs?

Antibiotics & treatment of Acute Bcterial Sinusitis. Walid Reda Product Manager. Do your antimicrobial options meet your needs? Antibiotics & treatment of Acute Bcterial Sinusitis Walid Reda Product Manager Do your antimicrobial options meet your needs? Antimicrobial Effects: What s involved? Effect in Humans: Serum concentration

More information

Acute Otitis Media in Pediatric Medicine Current Issues in Epidemiology, Diagnosis, and Management

Acute Otitis Media in Pediatric Medicine Current Issues in Epidemiology, Diagnosis, and Management REVIEW ARTICLE Pediatr Drugs 2003; 5 Suppl. 1: 1-12 1174-5878/03/0001-0001/$30.00/0 Adis Data Information BV 2003. All rights reserved. Acute Otitis Media in Pediatric Medicine Current Issues in Epidemiology,

More information

Comparison of cefpodoxime proxetil with cefaclor in the treatment of sinusitis

Comparison of cefpodoxime proxetil with cefaclor in the treatment of sinusitis Journal of Antimicrobial Chemotherapy () 6, Suppl. E, 87- Comparison of cefpodoxime proxetil with cefaclor in the treatment of sinusitis P. Gehanno", J. Depondt", B. Barry", M. Simonet* and H. Dewever"

More information

Antimicrobial prescribing pattern in acute tonsillitis: A hospital based study in Ajman, UAE

Antimicrobial prescribing pattern in acute tonsillitis: A hospital based study in Ajman, UAE Antimicrobial prescribing pattern in acute tonsillitis: A hospital based study in Ajman, UAE Lisha Jenny John 1*, Meenu Cherian 2, Jayadevan Sreedharan 3, Tambi Cherian 2 1 Department of Pharmacology,

More information

The World Health Organization has referred to. Antibiotic Resistance: The Iowa Experience DRUG UTILIZATION. Nancy Bell, RPh

The World Health Organization has referred to. Antibiotic Resistance: The Iowa Experience DRUG UTILIZATION. Nancy Bell, RPh DRUG UTILIZATION Antibiotic Resistance: The Iowa Experience Nancy Bell, RPh Background: In the past 10 years, the number of strains of Streptococcus pneumoniae and other common respiratory pathogens that

More information

Appropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases

Appropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses

More information

Bacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota

Bacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota Bacterial Resistance of Respiratory Pathogens John C. Rotschafer, Pharm.D. University of Minnesota Antibiotic Misuse ~150 million courses of antibiotic prescribed by office based prescribers Estimated

More information

Marc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium

Marc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

More information

National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults

National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014

More information

parameters were enhanced to develop new antimicrobial formulations CONSIDERATIONS IN ANTIMICROBIAL SELECTION Using animal models and human data, PK an

parameters were enhanced to develop new antimicrobial formulations CONSIDERATIONS IN ANTIMICROBIAL SELECTION Using animal models and human data, PK an Overview of Newer Antimicrobial Formulations for Overcoming Pneumococcal Resistance William A Craig, MD The pharmacokinetic (PK) and pharmacodynamic (PD) profile of an antimicrobial agent provides important

More information

Brief reports. Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae

Brief reports. Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae Journal of Antimicrobial Chemotherapy (1997) 40, 105 108 Brief reports JAC Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae Andreas Pikis a *, Jacob A. Donkersloot

More information

Antimicrobial Pharmacodynamics

Antimicrobial Pharmacodynamics Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they

More information

CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Antibiotics One of the most commonly used group of drugs In USA 23

More information

Outpatient Antimicrobial Therapy. Role of Antibacterials in Outpatient Treatment of Respiratory Tract Infection. Acute Bacterial Rhinosinusitis

Outpatient Antimicrobial Therapy. Role of Antibacterials in Outpatient Treatment of Respiratory Tract Infection. Acute Bacterial Rhinosinusitis Outpatient Antimicrobial Therapy B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy University of California San Francisco Role of Antibacterials in Outpatient Treatment

More information

Rational management of community acquired infections

Rational management of community acquired infections Rational management of community acquired infections Dr Tanu Singhal MD, MSc Consultant Pediatrics and Infectious Disease Kokilaben Dhirubhai Ambani Hospital, Mumbai Why is rational management needed?

More information

Short Course Antibiotic Therapy of Streptococcal Pharyngitis: Comparison of Clarithromycin with Amoxicillin/ Clavulanate and Cefuroxime Axetil

Short Course Antibiotic Therapy of Streptococcal Pharyngitis: Comparison of Clarithromycin with Amoxicillin/ Clavulanate and Cefuroxime Axetil Short Course Antibiotic Therapy of Streptococcal Pharyngitis: Comparison of Clarithromycin with Amoxicillin/ Clavulanate and Cefuroxime Axetil D. Adam, MD PhD, Munich, Germany H. Scholz, MD PhD, Berlin,

More information

Acute pharyngotonsillitis is one of the most common

Acute pharyngotonsillitis is one of the most common STATEMENT OF NEEDS Sore throat is an extremely frequent complaint in children and accounts for millions of pediatrician office visits every year. The diagnosis of pharyngotonsillitis should be supported

More information

Doxycycline for strep pneumonia

Doxycycline for strep pneumonia Doxycycline for strep pneumonia Antibiotic Levofloxacin (Levaquin) 750 mg, 500 mg for the treatment of respiratory, skin, and urinary tract infections, user reviews and ratings. 14-12-1995 John G. Bartlett,

More information

Amoxicillin clavulanic acid spectrum

Amoxicillin clavulanic acid spectrum Cari untuk: Cari Cari Amoxicillin clavulanic acid spectrum 14-8-2017 Amoxicillin and clavulanate potassium (AMC), also known as augmentin, is an antibiotic used to treat bacterial infections. AMC is available

More information

Choosing the Best Antibiotic in Problem Outpatient Infectious Disease Cases

Choosing the Best Antibiotic in Problem Outpatient Infectious Disease Cases Choosing the Best Antibiotic in Problem Outpatient Infectious Disease Cases Dr. Earl Rubin Associate Professor Department of Pediatrics Division of Infectious Diseases Montreal Children s Hospital Disclosures

More information

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory

More information

Approach to pediatric Antibiotics

Approach to pediatric Antibiotics Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus

More information

ce lesson Optimizing antibiotic therapy for common childhood respiratory infections By Susanne Moadebi, BSc Pharm, Pharm.D.

ce lesson Optimizing antibiotic therapy for common childhood respiratory infections By Susanne Moadebi, BSc Pharm, Pharm.D. Approved BY CCCEP FOR 1.5 CEUs CCCEP file #896-0309 This lesson has been approved for 1.5 CEUs by the Canadian Council on Continuing Edu ca tion in Pharmacy. Approved for 1.5 CEUs by l Ordre des pharmaciens

More information

GLOBAL ANTIBIOTIC RESEARCH & DEVELOPMENT PARTNERSHIP

GLOBAL ANTIBIOTIC RESEARCH & DEVELOPMENT PARTNERSHIP GLOBAL ANTIBIOTIC RESEARCH & DEVELOPMENT PARTNERSHIP CO-AMOXICLAV (AMOXICILLIN + CLAVULANATE) Dr. Marie-Claude BOTTINEAU Dr. Emmanuel BARON Summary of global estimates (CHERG 2013) ~ 6.6 million deaths

More information

Critical Appraisal Topic. Antibiotic Duration in Acute Otitis Media in Children. Carissa Schatz, BSN, RN, FNP-s. University of Mary

Critical Appraisal Topic. Antibiotic Duration in Acute Otitis Media in Children. Carissa Schatz, BSN, RN, FNP-s. University of Mary Running head: ANTIBIOTIC DURATION IN AOM 1 Critical Appraisal Topic Antibiotic Duration in Acute Otitis Media in Children Carissa Schatz, BSN, RN, FNP-s University of Mary 2 Evidence-Based Practice: Critical

More information

Let me clear my throat: empiric antibiotics in

Let me clear my throat: empiric antibiotics in Let me clear my throat: empiric antibiotics in respiratory tract infections Alexander John Langley, MD MS MPH Goals of this talk Overuse of antibiotics is a major issue, as a result many specialist medical

More information

Perichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV

Perichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV Empiric Antibiotics for Pediatric Infections Seen in ED NOTE: Choice of empiric antibiotic therapy must take into account local pathogen frequency and resistance patterns, individual patient characteristics,

More information

Does the Dose Matter?

Does the Dose Matter? SUPPLEMENT ARTICLE Does the Dose Matter? William A. Craig Department of Medicine, University of Wisconsin, Madison, Wisconsin Pharmacokinetic/pharmacodynamic (PK/PD) parameters, such as the ratio of peak

More information

Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.

Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds

More information

number Done by Corrected by Doctor Dr.Malik

number Done by Corrected by Doctor Dr.Malik number 27 Done by Fatimah Farhan Corrected by Basil Al-Bakri Doctor Dr.Malik Note: anything in red is just extra info and you will not be asked about it in the exam. In this sheet we will continue talking

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #65 (NQF 0069): Appropriate Treatment for Children with Upper Respiratory Infection (URI) National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL MEASURES:

More information

ARTICLE. Effect of a Standardized Pharyngitis Treatment Protocol on Use of Antibiotics in a Pediatric Emergency Department

ARTICLE. Effect of a Standardized Pharyngitis Treatment Protocol on Use of Antibiotics in a Pediatric Emergency Department ARTICLE Effect of a Standardized Pharyngitis Treatment Protocol on Use of Antibiotics in a Pediatric Emergency Department Maria Carmen G. Diaz, MD; Nadine Symons, MD; Maria L. Ramundo, MD; Norman C. Christopher,

More information

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical

More information

How Low Can We Go? Readdressing Antibiotic Duration for Common Childhood Infections

How Low Can We Go? Readdressing Antibiotic Duration for Common Childhood Infections How Low Can We Go? Readdressing Antibiotic Duration for Common Childhood Infections Rebecca Levorson, MD Andrew Nuibe, MD, MSCI Pediatric Infectious Diseases Disclosures Dr. Rebecca Levorson: I have no

More information

GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS

GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes

More information

Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?

Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Andrea Duppenthaler andrea.duppenthaler@insel.ch Limping patient local pain swelling tenderness warmth fever acute Osteomyelitis

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Treatment of community-acquired meningitis including difficult to treat organisms like penicillinresistant pneumococci and guidelines (ID perspective) Stefan Zimmerli, MD Institute for Infectious Diseases

More information

According to a recent National ... PRESENTATION...

According to a recent National ... PRESENTATION... ... PRESENTATION... in Treating Respiratory Tract Infections in an Age of Antibiotic Resistance Miguel Mogyoros, MD Presentation Summary Managing respiratory tract infections (RTIs) presents many challenges

More information

Outpatient Antimicrobial Therapy. Role of Antibacterials in Outpatient Treatment of Respiratory Tract Infection. Vicks Vapo Rub for Cold Symptoms

Outpatient Antimicrobial Therapy. Role of Antibacterials in Outpatient Treatment of Respiratory Tract Infection. Vicks Vapo Rub for Cold Symptoms Outpatient Antimicrobial Therapy B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy University of California San Francisco Role of Antibacterials in Outpatient Treatment

More information

Outpatient Antimicrobial Therapy. Role of Antibacterials in Outpatient Treatment of Respiratory Tract Infection. Vicks VapoRub

Outpatient Antimicrobial Therapy. Role of Antibacterials in Outpatient Treatment of Respiratory Tract Infection. Vicks VapoRub Outpatient Antimicrobial Therapy B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy University of California San Francisco Role of Antibacterials in Outpatient Treatment

More information

Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani

Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:

More information

Community Acquired Pneumonia: An Update on Guidelines

Community Acquired Pneumonia: An Update on Guidelines Community Acquired Pneumonia: An Update on Guidelines Claudia Summa, BScPhm Pharmacy Resident September 12, 2006 Objectives To give a brief description of the pathophysiology of community acquired pneumonia

More information

Antibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Antibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Antibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Sung Kyu Kim, M.D.Young Sam Kim, M.D. Department of Internal Medicine Yonsei University College of Medicine,

More information

Bacterial skin and soft tissues infections (SSTI) are one of the most common 1. infections among different age groups

Bacterial skin and soft tissues infections (SSTI) are one of the most common 1. infections among different age groups Bacterial skin and soft tissues infections (SSTI) are one of the most common 1 infections among different age groups Gram-positive bacteria are the most frequently isolated pathogens from SSTI, with a

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority Quality ID #65 (NQF 0069): Appropriate Treatment for Children with Upper Respiratory Infection (URI) National Quality Strategy Domain: Efficiency and Cost Reduction Meaningful Measure Area: Appropriate

More information

...CONTINUING MEDICAL EDUCATION...

...CONTINUING MEDICAL EDUCATION... ...CONTINUING MEDICAL EDUCATION...... Drug Resistance and the Treatment of Upper Respiratory Infections GOAL To provide comprehensive and up-to-date information concerning drug resistance and the implications

More information

J. M. Blondeau*, M. Suter, S. Borsos and the Canadian Antimicrobial Study Group

J. M. Blondeau*, M. Suter, S. Borsos and the Canadian Antimicrobial Study Group Journal of Antimicrobial Chemotherapy (1999) 43, Suppl. A, 25 30 JAC Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella

More information

Outpatient Antimicrobial Therapy. Role of Antibacterials in Outpatient Treatment of Respiratory Tract Infection. Acute Bacterial Rhinosinusitis

Outpatient Antimicrobial Therapy. Role of Antibacterials in Outpatient Treatment of Respiratory Tract Infection. Acute Bacterial Rhinosinusitis Outpatient Antimicrobial Therapy B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy University of California San Francisco Role of Antibacterials in Outpatient Treatment

More information

Volume 1; Number 7 November 2007

Volume 1; Number 7 November 2007 Volume 1; Number 7 November 2007 CONTENTS Page 1 Page 3 Guidance on the Use of Antibacterial Drugs in Lincolnshire Primary Care: Winter 2007/8 NICE Clinical Guideline 54: Urinary Tract Infection in Children

More information

CLINICAL USE OF BETA-LACTAMS

CLINICAL USE OF BETA-LACTAMS CLINICAL USE OF BETA-LACTAMS Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu WHY IS INFECTIOUS DISEASE PHARMACOTHERAPY SO CONFUSING? Microbial

More information

and Health Sciences, Wayne State University and Detroit Receiving Hospital, Detroit, MI, USA

and Health Sciences, Wayne State University and Detroit Receiving Hospital, Detroit, MI, USA Journal of Antimicrobial Chemotherapy (2004) 54, Suppl. S1, i7 i15 DOI: 10.1093/jac/dkh313 JAC Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae

More information

CME/CE QUIZ CME/CE QUESTIONS. a) 20% b) 22% c) 34% d) 35% b) Susceptible and resistant strains of typical respiratory

CME/CE QUIZ CME/CE QUESTIONS. a) 20% b) 22% c) 34% d) 35% b) Susceptible and resistant strains of typical respiratory CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for

More information

$100 $200 $300 $400 $500

$100 $200 $300 $400 $500 Skin is In Runny Noses Got to go! Hear no evil It s in the Lungs $100 $100 $100 $100 $100 $200 $200 $200 $200 $200 $300 $300 $300 $300 $300 $400 $400 $400 $400 $400 $500 $500 $500 $500 $500 Double Jeopardy

More information

Updated guideline for the management of upper respiratory tract infections in South Africa: 2008

Updated guideline for the management of upper respiratory tract infections in South Africa: 2008 Southern African Journal of Epidemiology and Infection ISSN: 1015-8782 (Print) (Online) Journal homepage: http://www.tandfonline.com/loi/ojid19 Updated guideline for the management of upper respiratory

More information

Burton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents

Burton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How

More information

10/9/2017. Evidence-Based Interventions to Reduce Inappropriate Prescription of Antibiotics. Prescribing for Respiratory Tract Infections

10/9/2017. Evidence-Based Interventions to Reduce Inappropriate Prescription of Antibiotics. Prescribing for Respiratory Tract Infections Evidence-Based Interventions to Reduce Inappropriate Prescription of Antibiotics Ann Thomas, MD, MPH Oregon Public Health Division Prescribing for Respiratory Tract Infections Antibiotic use is primary

More information

Annex II. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation

Annex II. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation Annex II Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation 1 Scientific conclusions Overall summary of the scientific evaluation of Amoxil and associated

More information

Responsible use of antibiotics

Responsible use of antibiotics Responsible use of antibiotics Uga Dumpis MD, PhD Department of Infectious Diseases and Infection Control Pauls Stradiņs Clinical University Hospital Challenges in the hospitals Antibiotics are still effective

More information

** the doctor start the lecture with revising some information from the last one:

** the doctor start the lecture with revising some information from the last one: Page 1 of 7 ** the doctor start the lecture with revising some information from the last one: #penicillin G has a good susceptibility against gram(+ve), Neisseria (-ve) #mostly active against strep. (don

More information

Management of Native Valve

Management of Native Valve Management of Native Valve Infective Endocarditis 2005 AHA 2015 Baddour LM, et al. Circulation. 2015;132(15):1435-86 2009 ESC 2015 Habib G, et al. Eur Heart J. 2015;36(44):3075-128 ESC 2015: Endocarditis

More information

Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J

Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J Record Status This is a critical abstract of an economic evaluation

More information

Telephone Max dose amoxicillin pediatrics P.O. Box 189 Navan, ON, K4B 1J4 Canada. Sitemap

Telephone Max dose amoxicillin pediatrics P.O. Box 189 Navan, ON, K4B 1J4 Canada. Sitemap Telephone 613-835-9490 Max dose amoxicillin pediatrics P.O. Box 189 Navan, ON, K4B 1J4 Canada Sitemap 25 mg/kg/ dose ( Max : 500 mg/ dose ) PO twice daily for 10 days is recommended by the Infectious Diseases

More information

WORKSHOP 6 Towards European consensus indications for major antibiotic classes: an exercise with the macrolides. Objectives

WORKSHOP 6 Towards European consensus indications for major antibiotic classes: an exercise with the macrolides. Objectives Objectives To establish the basic pharmacokinetic properties and safety profile of predefined macrolides. To make an inventory of the intrinsic susceptibilities of pathogenic organisms towards macrolides

More information

Quality ID #66: Appropriate Testing for Children with Pharyngitis National Quality Strategy Domain: Efficiency and Cost Reduction

Quality ID #66: Appropriate Testing for Children with Pharyngitis National Quality Strategy Domain: Efficiency and Cost Reduction Quality ID #66: Appropriate Testing for Children with Pharyngitis National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process

More information

ECHO: Management of URIs. Charles Krasner, M.D. Sierra NV Veterans Affairs Hospital University of NV, Reno School of Medicine October 16, 2018

ECHO: Management of URIs. Charles Krasner, M.D. Sierra NV Veterans Affairs Hospital University of NV, Reno School of Medicine October 16, 2018 ECHO: Management of URIs Charles Krasner, M.D. Sierra NV Veterans Affairs Hospital University of NV, Reno School of Medicine October 16, 2018 Infectious causes of URIs change over time Most ARIs are viral

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the

More information

P< cells/µl mg/dl P<0.01 P<0.01

P< cells/µl mg/dl P<0.01 P<0.01 Technical Reports Judicious Use of s for Pediatric Infection Global Strategies to Prevent the Increase of Bacterial Resistance Kazunobu OUCHI Principle of antimicrobial therapy in children is to select

More information

ARTICLE. Antibiotic Prescribing by Primary Care Physicians for Children With Upper Respiratory Tract Infections

ARTICLE. Antibiotic Prescribing by Primary Care Physicians for Children With Upper Respiratory Tract Infections ARTICLE Antibiotic Prescribing by Primary Care Physicians for Children With Upper Respiratory Tract Infections David R. Nash, MD; Jeffrey Harman, PhD; Ellen R. Wald, MD; Kelly J. Kelleher, MD Objectives:

More information

moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering

moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering 05 November 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above

More information

Resistance Among Streptococcus pneumoniae: Patterns, Mechanisms, Interpreting the Breakpoints

Resistance Among Streptococcus pneumoniae: Patterns, Mechanisms, Interpreting the Breakpoints ...PRESENTATIONS... Resistance Among Streptococcus pneumoniae: Patterns, Mechanisms, Interpreting the Breakpoints Angela B. Brueggemann, MS; and Gary V. Doern, PhD Presentation Summary Streptococcus pneumoniae

More information

Cefuroxime vs cefpodoxime

Cefuroxime vs cefpodoxime Cefuroxime vs cefpodoxime Pictures of Omnicef (Cefdinir), drug imprint information, side effects for the patient. Quinolone antibiotic Ciprofloxacin (Cipro) for urinary tract infections (UTI), cystitis,

More information

ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae

ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062

More information

Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?

Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? With the support of Wallonie-Bruxelles-International 1-1 In vitro evaluation of antibiotics : the antibiogram

More information

Vaccination as a potential strategy to combat Antimicrobial Resistance in the elderly

Vaccination as a potential strategy to combat Antimicrobial Resistance in the elderly Vaccination as a potential strategy to combat Antimicrobial Resistance in the elderly Wilbur Chen, MD, MS 22-23 March 2017 WHO meeting on Immunization of the Elderly The Problem Increasing consumption

More information

Updated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007

Updated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007 Updated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007 1 Ongoing data from CDC 's Gonococcal Isolate Surveillance Project (GISP), including

More information

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How

More information

Emergence of Antibiotic Resistance in Upper and

Emergence of Antibiotic Resistance in Upper and ...PRESENTATIONS... Emergence of Antibiotic Resistance in Upper and Lower Respiratory Tract Infections Michael R. Jacobs, MB, BCh, PhD Presentation Summary The increase in antibiotic resistance is of great

More information

choice The Rilexine Palatable Tablets First generation cephalosporin for skin infections Now registered for ONCE daily administration*

choice The Rilexine Palatable Tablets First generation cephalosporin for skin infections Now registered for ONCE daily administration* Virbac Dermatology Palatable Tablets The choice First generation cephalosporin for skin infections Now registered for ONCE daily administration* are only available under Veterinary Authorisation. www.virbac.co.nz

More information

ORIGINAL ARTICLE. Focus Technologies, Inc., 1 Hilversum, The Netherlands, 2 Herndon, Virginia and 3 Franklin, Tennessee, USA

ORIGINAL ARTICLE. Focus Technologies, Inc., 1 Hilversum, The Netherlands, 2 Herndon, Virginia and 3 Franklin, Tennessee, USA ORIGINAL ARTICLE In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000 2001 M. E. Jones 1, R. S. Blosser-Middleton

More information

Outpatient Antimicrobial Therapy. Role of Antibacterials in Outpatient Treatment of Respiratory Tract Infection. Vicks VapoRub

Outpatient Antimicrobial Therapy. Role of Antibacterials in Outpatient Treatment of Respiratory Tract Infection. Vicks VapoRub Outpatient Antimicrobial Therapy B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy University of California San Francisco Role of Antibacterials in Outpatient Treatment

More information

Otitis Media. TOM PARTNER, NP suggestions

Otitis Media. TOM PARTNER, NP suggestions Otitis Media TOM PARTNER, NP suggestions Treat Children with Omnicef (cedinir) as first choice because of less likely allergic reaction 14 mg /kg/ d (Once a day x 10 days) but do not exceed total of 600

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority Quality ID #66: Appropriate Testing for Children with Pharyngitis National Quality Strategy Domain: Efficiency and Cost Reduction Meaningful Measure Area: Appropriate Use of Healthcare 2019 COLLECTION

More information

UTI Dr S Mathijs Department of Pharmacology

UTI Dr S Mathijs Department of Pharmacology UTI Dr S Mathijs Department of Pharmacology Introduction Responsible for > 7 million consultations annually 15% of all antibiotic prescriptions 40% of all hospital acquired infections Significant burden

More information

Antimicrobial Stewardship in Ambulatory Care

Antimicrobial Stewardship in Ambulatory Care Antimicrobial Stewardship in Ambulatory Care Nila Suntharam, M.D. May 5, 2017 Dr. Suntharam indicated no potential conflict of interest to this presentation. She does not intend to discuss any unapproved/investigative

More information

Report on New Patented Drugs - Ketek

Report on New Patented Drugs - Ketek Report on New Patented Drugs - Ketek October 2006 Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB

More information

B. PACKAGE LEAFLET 1

B. PACKAGE LEAFLET 1 B. PACKAGE LEAFLET 1 PACKAGE LEAFLET NICILAN 400 mg/100 mg tablets for dogs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH

More information

Pharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements

Pharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements Pharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements should be avoided. PDR Drug Summaries are concise point-of-care

More information

Medical bacteriology Lecture 8. Streptococcal Diseases

Medical bacteriology Lecture 8. Streptococcal Diseases Medical bacteriology Lecture 8 Streptococcal Diseases Streptococcus agalactiae Beat haemolytic Lancifield group B Regularly resides in human vagina, pharynx and large inine Can be transferred to infant

More information

Cephalosporins, Quinolones and Co-amoxiclav Prescribing Audit

Cephalosporins, Quinolones and Co-amoxiclav Prescribing Audit Cephalosporins, Quinolones and Co-amoxiclav Prescribing Audit Executive Summary Background Antibiotic resistance poses a significant threat to public health, as antibiotics underpin routine medical practice.

More information

Suggested treatment. Inj Crystalline Penicillin 50,000U/Kg i.v. 4-6hrly (if child cannot swallow) 40mg/Kg/dose BID x 10days

Suggested treatment. Inj Crystalline Penicillin 50,000U/Kg i.v. 4-6hrly (if child cannot swallow) 40mg/Kg/dose BID x 10days GUIDELINES FOR TREATMENT OF INFECTIONS IN CHILDREN A. RESPIRATORY TRACT INFECTIONS UPPER RESPIRATORY TRACT INFECTIONS Infection/Condition/likely organism Suggested treatment Preferred Alternative Acute

More information

4/10/2014. Prof.Dr.Mohamed Bassiouny Professor of Otolaryngology Alexandria University.

4/10/2014. Prof.Dr.Mohamed Bassiouny Professor of Otolaryngology Alexandria University. Prof.Dr.Mohamed Bassiouny Professor of Otolaryngology Alexandria University. 1 Aim When? What? For how long? Antibiotic Hamada, 5 month old baby referred to your office C/O ; Irritability, fever, vomiting

More information

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to

More information